- Associated Press - Monday, October 27, 2014

NEW YORK (AP) - Australian drugmaker CSL Ltd. said Monday it will buy Novartis’ flu vaccine business for $275 million.

CSL Ltd. said the deal will make it the second-largest flu vaccine maker in the world. The company said the Novartis business had $527 million in revenue in 2013 and said its combined revenue could reach $1 billion a year in three to five years.

Novartis flu vaccines include Flucelvax, Fluvirin and Fluad. The Switzerland-based company, which expects to ship about 60 million doses worldwide of its seasonal influenza vaccines for the 2014-2015 season, reported $57.92 billion in total revenue in 2013.

Shares of Novartis AG picked up 24 cents to $90.39 in midday trading.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide